Grünenthal Acquires Cancer Treatment for EBITDA Boost

AACHEN, Germany, Sept. 21, 2026 /CourierPR/ -- Grünenthal, a global leader in pain management and research, has announced its acquisition of Stivarga®, an oral treatment for specific advanced cancers. The acquisition, which is subject to customary closing conditions including regulatory approvals, is expected to close by the end of 2026 or early 2027. This move marks the latest step in Grünenthal's strategy to acquire established medicines that serve clear medical needs, leverage its commercial and operational capabilities, and drive growth.

Stivarga® (regorafenib) is an established oral treatment for certain advanced cancers, including metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (liver cancer). It is approved and available in more than 90 markets worldwide. The acquisition of Stivarga® is a strategic fit for Grünenthal, aligning with the company's disciplined M&A strategy of acquiring established medicines that address clear and ongoing medical needs and create long-term value.

Stivarga® is an oral multikinase inhibitor indicated for metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (liver cancer) in patients who have already been treated with, or who cannot be given, other available treatments. The acquisition is expected to contribute positively to Grünenthal's EBITDA, with an estimated impact of up to approximately €100 million for the year ending 31 December 2027, based on an analysis of the information made available to Grünenthal from Bayer and assuming closing by the end of 2026 or the beginning of 2027, as well as a full-year consolidation.

The acquisition of Stivarga® is part of Grünenthal's ongoing M&A strategy, which has seen the company invest around €2.6 billion in successful M&A transactions since 2017. These acquisitions have included the global rights to Nebido™, the rights to Cialis® in Mexico, Brazil, and Colombia, the European rights to Crestor™ and Nexium™, and the global rights to Vimovo™ (ex-US and Japan), Zomig™ (ex-Japan), and Qutenza™. In addition to asset acquisitions, Grünenthal has also acquired full ownership of Grünenthal Meds, a previously joint venture with Kyowa Kirin International to market its established medicines portfolio, and acquired the US company Valinor Pharma and the product Movantik®.

Grünenthal, headquartered in Aachen, Germany, is a global leader in pain management and related diseases. The company focuses all its activities and efforts on working towards its vision of a World Free of Pain. In 2025, Grünenthal employed around 4,100 people and achieved revenues of €1.8 billion.

The acquisition of Stivarga® is a significant step in Grünenthal's strategy to expand its portfolio of established medicines and enhance its market reach, particularly in the field of cancer treatment. By integrating Stivarga® into its existing operations, Grünenthal aims to leverage its expertise in commercial and operational capabilities to maximize the value of the medicine and support its long-term growth objectives.